Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Safety and efficacy of bivalirudin in high-risk patients admitted through the emergency department.

Miller CD, Blomkalns AL, Gersh BJ, Pollack CV, Brogan GX, Diercks DB, Peacock WF, Stone GW, Hollander JE, Manoukian SV, Hoekstra JW; ACUITY Investigators.

Acad Emerg Med. 2009 Aug;16(8):717-25. doi: 10.1111/j.1553-2712.2009.00417.x.

2.

Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.

Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ; ACUITY Investigators.

JAMA. 2007 Dec 5;298(21):2497-506.

PMID:
18056903
3.

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.

Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD; ACUITY Investigators.

JAMA. 2007 Feb 14;297(6):591-602.

PMID:
17299194
4.

Bivalirudin for patients with acute coronary syndromes.

Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM; ACUITY Investigators.

N Engl J Med. 2006 Nov 23;355(21):2203-16.

Supplemental Content

Loading ...
Support Center